No Data
No Data
No Data
Express News | Tenaya Therapeutics Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Tenaya Therapeutics Announced Presentation Of TN-201 Gene Therapy Data For MYBPC3-Associated Hypertrophic Cardiomyopathy At ACC 2025 In Chicago; Includes 1-Year Patient Assessments From MyPEAK-1 Phase 1b/2 Trial
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Tenaya Therapeutics Price Target Cut to $6.00/Share From $18.00 by Canaccord Genuity
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity